Back to Search
STEVEN MARSHALL GORE MEDICAL DOCTOR MD
MEDICAL DOCTOR MD
Cardiovascular Disease Physician
NPI: 1346341633IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
2012-00575(NC)
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
2012-00575(NC)
Specialist
Specialist
Code: 174400000X
2012-00575(NC)
Education
UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE
Class of 2001
Research & Publications (20)
Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.
PMID 18813208·Cancer Control·2008
6-review
A method for optimising excision of the nail bed matrix.
PMID 17950199·J Hand Surg Eur Vol·2007
8-other
Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
PMID 16403407·J Natl Compr Canc Netw·2006
6-review
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
PMID 16778214·Cancer Res·2006
8-other
Mirror ear: a reconstructive technique for substantial tragal anomalies or polyotia.
PMID 16749196·J Plast Reconstr Aesthet Surg·2006
8-other
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
PMID 15929100·Am J Hematol·2005
8-other
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
PMID 16341238·Nat Clin Pract Oncol·2005
6-review
Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration.
PMID 16207305·J Vet Pharmacol Ther·2005
7-preclinical
Inhibitors of signaling in myelodysplastic syndrome.
PMID 15494298·Best Pract Res Clin Haematol·2004
6-review
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11948101·Clin Cancer Res·2002
3-trial
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11489809·Clin Cancer Res·2001
3-trial
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
PMID 11093362·Expert Opin Investig Drugs·2000
6-review
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations.
PMID 19464085·Eur J Med Chem·2009
8-other
Design, synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach.
PMID 19036593·Bioorg Med Chem·2009
7-preclinical
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
PMID 19167676·Biol Blood Marrow Transplant·2009
6-review
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
PMID 19230772·Lancet Oncol·2009
3-trial
Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
PMID 19479712·J Pathol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 32 PHYSICIAN DR
CLYDE, NC 28721 - Phone
- (828) 564-9222
Quick Facts
- NPI
- 1346341633
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 25
- Publications
- 20
Are you this provider?
Claim Your Profile